SCHEMBL1542759

SCHEMBL1542759

COc1c(C(=O)Nc2cccc(O)c2C)cc(-c2ccc[nH]c2=O)cc1C(C)(C)C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CD274 Q9NZQ7 4/20 0.47
CYP3A4 P08684 3/20 0.45
BTK Q06187 4/20 0.43
KDM4E B2RXH2 2/20 0.38
PKM P14618 1/20 0.38
NPC1 O15118 1/20 0.37
LMNA P02545 1/20 0.37
TP53 P04637 1/20 0.37
TSHR P16473 1/20 0.37
HTT P42858 1/20 0.37
RAB9A P51151 1/20 0.37
HSD17B10 Q99714 1/20 0.37
NR1H4 Q96RI1 2/20 0.37
PPARG P37231 1/20 0.37
ADORA3 P0DMS8 1/20 0.36
CFTR P13569 1/20 0.36
ADRB3 P13945 1/20 0.36
TBXA2R P21731 1/20 0.36
SLC6A2 P23975 1/20 0.36
AGTR1 P30556 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1542425 0.88 CYP3A4 (0.47) CD274CYP3A4BTKKDM4EPKM
SCHEMBL2128285 0.88 KDM4E (0.49) CD274CYP3A4BTKKDM4EPKM
SCHEMBL1542824 0.82 CYP3A4 (0.52) CYP3A4KDM4ETP53HTTNR1H4
SCHEMBL1542202 0.79 CYP3A4 (0.60) CD274CYP3A4KDM4EPKMLMNA
SCHEMBL1542874 0.79 CYP3A4 (0.51) CD274CYP3A4KDM4ENPC1TP53
SCHEMBL2127583 0.79 CYP3A4 (0.50) CYP3A4KDM4ENPC1LMNATP53
SCHEMBL2128598 0.78 CYP3A4 (0.54) CYP3A4PTGS2ALDH1A1L3MBTL1
SCHEMBL1543054 0.78 CYP3A4 (0.44) CD274CYP3A4BTKKDM4ELMNA
SCHEMBL1542683 0.78 CYP3A4 (0.61) CYP3A4KDM4ENPC1TP53RAB9A
SCHEMBL2128506 0.78 CYP3A4 (0.51) CYP3A4HTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8273773-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-09-25 US claimed
EP-2307372-B1 HETEROCYCLIC ANTIVIRAL COMPOUNDS HOFFMANN LA ROCHE (CH) 2012-04-25 EP claimed
EP-2307372-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2011-04-13 EP claimed
WO-2010010017-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2010-01-28 WO claimed
US-20100021423-A1 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2010-01-28 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100021423-A1 Heterocyclic antiviral compounds POLR2A, RRM2B, RRP1B CD274 3357/4885CYP3A4 528/4885BTK 2299/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.